Artificial intelligence is revolutionizing drug discovery and antibody engineering, accelerating the creation of new ...
Milestone Pharmaceuticals Inc.’s CARDAMYST nasal spray wins FDA approval for PSVT, but faces tough competition and market ...
Caffeine offers some real health benefits—but not if you go overboard. Here’s how coffee, energy drinks, and other caffeine ...
Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting bacteria that cause tuberculosis. The team have produced a compound that inhibits ...
8don MSN
Novel compound attacks tuberculosis bacteria's ATP synthase, showing promise against drug resistance
Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting ...
Is it bad to have a cup of coffee with breakfast? Not at all. Scientific studies have been highlighting the benefits of this ...
The FDA has approved intranasal etripamil (Cardamyst; Milestone Pharmaceuticals) for the acute treatment of paroxysmal supraventricular tachycardia (PSVT), making it the first self-administered, ...
From small ions to large molecules, cellular gates control what can pass in and out of cells. But how one such gate, called ...
December 16 is National Chocolate-Covered Anything Day, which is either a celebration of culinary creativity or an excuse to ...
Subject to TSX Venture Exchange (“ TSXV ”) approval, NurExone has engaged Russo Partners LLC, a New York–based strategic ...
By designing a squaric acid amide that binds a new site on ATP synthase, researchers created PRP020, a potential therapy for ...
Turning off the genetic switch to its respiratory system might finally eliminate the bacteria behind tuberculosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback